Abstract
Ribociclib is a kinase inhibitor. The active pharmaceutical ingredient Ribociclib is developed in the form of its succinate salt to improve physicochemical stability, manufacturability, and solid‑state consistency. The succinate salt exhibits enhanced crystallinity, improved filtration characteristics, and robust scalability compared to the free base.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Anonymous, "METHOD OF PREPARING CRYSTALLINE FORM A OF RIBOCICLIB SUCCINATE", Technical Disclosure Commons, (March 11, 2026)
https://www.tdcommons.org/dpubs_series/9494
COinS